½ÃÀ庸°í¼­
»óǰÄÚµå
1559490

Àç»ýÀÇ·áÀÇ ±â¼ú Áøº¸

Technological Advances in Regenerative Medicine

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Frost & Sullivan | ÆäÀÌÁö Á¤º¸: ¿µ¹® 55 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÆÄ±«ÀûÀÎ ±â¼ú ¹× °æÀï ȯ°æÀº Áٱ⼼Æ÷ Ä¡·á ¿¬±¸ÀÇ ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.

Àç»ýÀÇ·á´Â Å©°Ô ¹ßÀüÇÏ¿© ¿À´Ã³¯ ¿©·¯ °¡Áö Áٱ⼼Æ÷ Ä¡·á¹ýÀÌ »ó¿ëÈ­µÇ¾ú½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ´ë±Ô¸ð »ý»ê ¹× ¼¼Æ÷ ǰÁú°ú °ü·ÃµÈ ¹®Á¦¸¦ ±Øº¹Çϱâ À§ÇØ Áٱ⼼Æ÷ Ä¡·á¿¡¼­ ÁÖ¸ñÇÒ ¸¸ÇÑ ±â¼ú °³¹ßÀ» ¼öÇàÇß½À´Ï´Ù. Áٱ⼼Æ÷ ¿¬±¸´Â Áß°£¿± Áٱ⼼Æ÷³ª Á¶Ç÷¸ð¼¼Æ÷º¸´Ù À¯µµ¸¸´ÉÁٱ⼼Æ÷¿¡ ÃÊÁ¡À» ¸ÂÃß°í Àִµ¥, ÀÌ´Â iPS ¼¼Æ÷ ¿¬±¸ÀÇ ±Þ¼ÓÇÑ ¹ßÀü¿¡ ±âÀÎÇÕ´Ï´Ù. ±â¼ú Ç÷§ÆûÀÇ °³¹ßÀº Àüü Áٱ⼼Æ÷ Ä¡·á¿Í ¼±ÅÃÀ» °³¼±Çϰí Àüü ºñ¿ëÀ» Àý°¨ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½Å»ý ±â¾÷Àº ¼¼Æ÷ÀÇ »ýÁ¸À²°ú À¯ÁöÀ²À» ÀÏÁ¤ÇÏ°Ô À¯ÁöÇϱâ À§ÇØ »õ·Î¿î ¼¼Æ÷ ºÐ¸®, Ư¼ºÈ­ ¹× ½ºÅ©¸®´× ÇÁ·Î¼¼½º¸¦ È®¸³Çϰí ÀÖ½À´Ï´Ù.

¾÷°è´Â Áٱ⼼Æ÷ À̹Ì¡, ½Ç½Ã°£ ÃßÀû, »õ·Î¿î Áúº´ ¿µ¿ªÀ¸·ÎÀÇ ÁøÀÔÀ» À§ÇØ ÀΰøÁö´É°ú ¸Ó½Å·¯´× ±â¼úÀ» Á¡Á¡ ´õ ¸¹ÀÌ µµÀÔÇϰí ÀÖ½À´Ï´Ù. Áٱ⼼Æ÷ Ä¡·á´Â Èñ±ÍÁúȯ ¿Ü¿¡µµ Á¾¾ç, ½Å°æÁúȯ, ½ÉÀåÁúȯ Ä¡·á¿¡µµ Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¹Î°£ ÅõÀÚ¿Í °øµ¿¿¬±¸´Â Áٱ⼼Æ÷ ¿¬±¸°³¹ßÀ» ÃËÁøÇÏ°í ´Ù¾çÇÑ Áúȯ¿¡ ´ëÇÑ ÀÓ»ó½ÃÇè ÆÄÀÌÇÁ¶óÀÎÀ» Áö¼ÓÀûÀ¸·Î ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­´Â Áٱ⼼Æ÷ Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ ÀÌÇØ°ü°èÀÚµéÀÌ °í¾ÈÇÑ ´Ü°èÀû ±â¼ú °³¼±°ú »õ·Î¿î Ç÷§Æû, Áï Àΰø´Ù´É¼º Áٱ⼼Æ÷, Áß°£¿± Áٱ⼼Æ÷, Á¶Ç÷¸ð¼¼Æ÷, Àΰ£ ¹è¾ÆÁٱ⼼Æ÷ µî Áٱ⼼Æ÷ Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ »õ·Î¿î Ç÷§Æû¿¡ ´ëÇØ »ìÆìº¾´Ï´Ù.

ÀÌ ¼³¹®Á¶»ç°¡ ´Ù·ç´Â ÁÖ¿ä Áú¹®

Áٱ⼼Æ÷ Ä¡·áÀÇ ÇöȲ°ú Àü¹ÝÀûÀÎ µ¿ÇâÀº? Áٱ⼼Æ÷ Ä¡·áÀÇ ¿¬±¸°³¹ßÀ» Çâ»ó½ÃŰ´Â ±â¼ú °³¹ßÀº ¹«¾ùÀΰ¡? Áٱ⼼Æ÷Ä¡·áÁ¦ ¿¬±¸°³¹ßÀ» È®´ëÇϱâ À§ÇØ »õ·Î¿î ±â¼ú Ç÷§ÆûÀ» äÅÃÇϰí ÀÖ´Â ±â¾÷Àº? Áٱ⼼Æ÷Ä¡·áÁ¦ °³¹ßÀÇ ÅõÀÚ ¹× ÆÄÆ®³Ê½Ê »ýŰè´Â ¾î¶»°Ô Çü¼ºµÇ¾î Àִ°¡?

¸ñÂ÷

Àü·«Àû °úÁ¦

  • ¿Ö ¼ºÀåÀÌ ¾î·Á¿öÁö°í Àִ°¡?
  • The Strategic Imperative 8(TM)
  • ¼¼Æ÷¡¤À¯ÀüÀÚ Ä¡·á ¾÷°è¿¡¼­ Àü·«Àû Áß¿ä °úÁ¦ TOP 3ÀÇ ¿µÇâ
  • Growth Pipeline Engine(TM)ÀÇ ¼ºÀå ±âȸ
  • Á¶»ç ¹æ¹ý

¼ºÀå ±âȸ ºÐ¼®

  • ºÐ¼® ¹üÀ§
  • ¼¼ºÐÈ­

¼ºÀå¿äÀÎ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • Àç»ýÀÇ·á¿¡¼­ ÀϹÝÀûÀÎ Áٱ⼼Æ÷ÀÇ À¯Çü
  • Áٱ⼼Æ÷ Ä¡·á °³¹ßÀÇ Àüü µ¿Çâ
  • Àç»ýÀÇ·á »óȲÀÇ ÇöȲ

¼ºÀå¿äÀÎ

  • Áٱ⼼Æ÷ Ä¡·á °³¹ß¿¡¼­ Áö¼ÓÀû °úÁ¦
  • Àç»ýÀÇ·á °³¹ß¿¡ ÀÓ»ó ÀÀ¿ëµÇ´Â Áٱ⼼Æ÷
  • iPS ¼¼Æ÷Ä¡·áÀÇ ÁøÀü
  • MSCÀÇ °³¹ß
  • Á¶Ç÷¸ð¼¼Æ÷ÀÇ °³¹ß
  • hESC ¿ä¹ýÀÇ °³¹ß
  • Áٱ⼼Æ÷ Ä¡·á °³¹ßÀÚ¿¡ ÀÇÇÑ ÀüüÀûÀÎ ±â¼ú µµÀÔ
  • Áٱ⼼Æ÷ °³¹ßÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ¼¼Æ÷ Á¦Á¶ Ç÷§Æû
  • Áٱ⼼Æ÷ ¼±Åðú Ư¼º Æò°¡ Ç÷§Æû
  • Áٱ⼼Æ÷ Ä¡·á °³¹ßÀ» À§ÇÑ AI ÅëÇÕ Ç÷§Æû
  • Áٱ⼼Æ÷ Ä¡·á °³¹ßÀ» À§ÇÑ AI Ç÷§Æû
  • ´Ù¾çÇÑ Áúȯ ¿µ¿ª¿¡¼­ Áٱ⼼Æ÷ Ä¡·áÀÇ ¿µÇâ

Áٱ⼼Æ÷ ¿¬±¸, ¹Î°£ ¹× °øÀû ÅõÀÚ »óȲ

  • Áٱ⼼Æ÷ Ä¡·á¸¦ ÃßÁøÇÏ´Â °øÀû ÅõÀÚ µ¿Çâ
  • Áٱ⼼Æ÷ ¿¬±¸¸¦ ÃËÁøÇÏ´Â ÃÖ±Ù ¹Î°£ÅõÀÚ µ¿Çâ
  • Áٱ⼼Æ÷ Ä¡·á¿¡¼­ M&AÀÇ Áõ°¡
  • ÆÄÆ®³Ê½ÊÀÇ È®´ë

¼ºÀå ±âȸ À¯´Ï¹ö½º

  • ¼ºÀå ±âȸ 1 : Áٱ⼼Æ÷ È®À强À» Çâ»ó½ÃŰ´Â AI¿Í ÀÚµ¿È­ÀÇ ÅëÇÕ
  • ¼ºÀå ±âȸ 2 : Áٱ⼼Æ÷ ÁúÀ» Çâ»ó½ÃŰ´Â ¼¼Æ÷ °øÇаú ¸®ÇÁ·Î±×·¡¹Ö¹ý
  • ¼ºÀå ±âȸ 3 : ¿ì¼± ¾Ï¿¡ ÃÊÁ¡À» ¸ÂÃß°í, ´ÙÀ½À¸·Î Èñ±ÍÁúȯ¿¡ ÃÊÁ¡À» ¸ÂÃá´Ù.

ºÎ·Ï

  • ±â¼ú Áغñ ·¹º§(TRL) : ÇØ¼³

´ÙÀ½ ½ºÅÜ

  • ¼ºÀå ±âȸÀÇ ÀÌÀͰú ¿µÇâ
  • ´ÙÀ½ ½ºÅÜ
  • ¸éÃ¥»çÇ×
KSA 24.10.14

Disruptive Technology and a Competitive Landscape Drive Growth in Stem Cell Therapy Research

Regenerative medicine has evolved significantly and today includes several commercialized stem cell therapies. Researchers have made notable technological developments in stem cell therapies to overcome challenges related to large-scale manufacturing and cell quality. Stem cell research is more focused on induced pluripotent stem cells than on mesenchymal and hematopoietic stem cells, a transition caused by the fast-paced developments in iPSC research. Developments in technology platform help improve overall stem cell therapy and selection and reduce overall costs. Emerging companies are establishing newer cell isolation, characterization, and screening processes to ensure constant cell viability and maintenance.

Industry players increasingly adopt artificial intelligence and machine learning technologies for stem cell imaging, real-time tracking, and entering new disease areas. Stem cell therapies have huge potential in treating oncology, neurological conditions, and cardiac conditions, apart from rare diseases. Private investments and collaborations continue to drive stem cell R&D and push the clinical trial pipelines across various diseases.

This report covers incremental technological improvements and the new platforms that stakeholders have designed for stem cell therapy developments in induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and human embryonic stem cells.

Key Questions This Study Addresses:

What is the current landscape of stem cell therapy, and what are the overall trends? What are the technology developments improving stem cell therapy R&D? Which companies are adopting new technology platforms to scale stem cell therapy R&D? What is the investment and partnership ecosystem in stem cell therapy development?

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Cell and Gene Therapy Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™
  • Research Methodology

Growth Opportunity Analysis

  • Scope of Analysis
  • Segmentation

Growth Generator

  • Growth Drivers
  • Growth Restraints
  • Types of Common Stem Cells in Regenerative Medicine
  • Overall Trends in Stem Cell Therapy Development
  • Snapshot of the Regenerative Medicine Landscape

Growth Generator

  • Ongoing Challenges in the Development of Stem Cell Therapy
  • Highly Adopted Stem Cells in Clinical Use to Develop Regenerative Medicine
  • Developments in iPSC Therapies
  • Developments in MSCs
  • Developments in HSCs
  • Developments in hESC Therapies
  • Overall Technology Adoption by Stem Cell Therapy Developers
  • Cell Manufacturing Platforms Enabling Stem Cell Development
  • Stem Cell Selection and Characterization Platform
  • AI-integrated Platforms for Stem Cell Therapy Developments
  • AI Platforms for Stem Cell Therapy Development
  • Impact of Stem Cell Therapies in Various Diseases Areas

Stem Cell Research, Private and Public Investment Landscape

  • Public Investment Trends Driving Stem Cell Therapy Research
  • Recent Private Investments Driving Stem Cell Therapy Research
  • Growing M&As in Stem Cell Therapy
  • Growing Partnerships

Growth Opportunity Universe

  • Growth Opportunity 1: Integration of AI and Automation to Improve Stem Cell Scalability
  • Growth Opportunity 2: Cell Engineering and Reprogramming Methods to Improve Stem Cell Quality
  • Growth Opportunity 3: Focus on Cancer First and then on Rare Diseases

Appendix

  • Technology Readiness Level (TRL): Explanations

Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • Legal Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦